Skip to main content

Drug Interactions between bendamustine and Zegerid OTC

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

omeprazole bendamustine

Applies to: Zegerid OTC (omeprazole / sodium bicarbonate) and bendamustine

MONITOR: Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its pharmacologically active metabolites. In vitro, bendamustine has been shown to undergo metabolism via CYP450 1A2 to two minor cytotoxic metabolites, M3 and M4. Because concentrations of these metabolites in plasma are normally just 1/10 and 1/100 that of the parent drug, respectively, their overall contribution to the cytotoxicity of bendamustine is unknown. As such, the potential effect of CYP450 1A2 induction is unknown.

MANAGEMENT: Caution is advised if bendamustine is used in combination with CYP450 1A2 inducers. Patients should be monitored for potentially altered effects of bendamustine.

References

  1. "Product Information. Treanda (bendamustine)." Cephalon Inc (2008):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer